Nicotinic Antagonists

Drugs that bind to nicotinic cholinergic receptors (RECEPTORS, NICOTINIC) and block the actions of acetylcholine or cholinergic agonists. Nicotinic antagonists block synaptic transmission at autonomic ganglia, the skeletal neuromuscular junction, and at central nervous system nicotinic synapses.

Also Known As:

Networked: 24 relevant articles (0 outcomes, 0 trials/studies)

Bio-Agent Context: Research Results

Experts

1.	Baxter, Mark G: 1 article (10/2021)
2.	Upright, Nicholas A: 1 article (10/2021)
3.	Dhanarisi, Jeevan: 1 article (01/2020)
4.	Eddleston, Michael: 1 article (01/2020)
5.	Gawarammana, Indika: 1 article (01/2020)
6.	Harju, Kirsi: 1 article (01/2020)
7.	Kostiainen, Olli: 1 article (01/2020)
8.	Mohamed, Fahim: 1 article (01/2020)
9.	Shahmy, Seyed: 1 article (01/2020)
10.	Shihana, Fathima: 1 article (01/2020)

Related Diseases

1.	Ganglion Cysts (Ganglion) 02/01/1997 - "In addition, nicotinic antagonists reduced the light-driven input to DS ganglion cells by approximately 50%. " 03/11/1988 - "The postsynaptic effect of endogenous or applied ACh on the ganglion cells can be blocked with specific nicotinic antagonists. " 10/01/1978 - "2 The possibility that at least part of the excitatory pathway was interrupted as a ganglion synapse lying in one of the nodes of plexus close to the muscle was suggested by the observations that (a) the excitatory response to extrinsic nerve stimulation was reduced by the nicotinic antagonists tubocurarine (0.13 to 0.26 mM) and dihydro beta-erythroidine (0.1 to 0.14 mM). " 01/01/1987 - "ACh nicotinic antagonists [hexamethonium, D-tubocurarine (D-TC), alpha-bungarotoxin (alpha-BGTX)] provoked an increase of the receptive field area of On-Off ganglion cells, this enlargement being due to the suppression of the inhibition normally exerted by the surround upon the centre of the field. "
2.	Poisoning 01/01/2020 - "Further clinical research, including testing of shorter duration regimens, needs to be performed before nicotinic antagonists can be used in the clinical management of OP poisoning." 07/01/2005 - "Nicotinic antagonists and nerve gas poisoning."
3.	Pain (Aches) 07/15/2013 - "Agonists/partial agonists of α4β2* neuronal nicotinic acetylcholine receptor show efficacy in animal models of pain and their anti-nociceptive properties are blocked by nicotinic antagonists. " 10/01/1999 - "Nicotinic antagonists, mecamylamine and dihydro-beta-erythroidine, blocked metanicotine-induced antinociception in the different pain models. "
4.	Hypoxia (Hypoxemia) 10/01/2007 - "In the presence of nicotinic antagonists, the responses in prenatal nicotine animals reverted to the pattern of responses in unexposed animals in which an increase in glutamatergic neurotransmission occurred not during but only on recovery from hypoxia/hypercapnia, and this recruited excitatory pathway was blocked by P2 receptor antagonists. " 01/01/2019 - "Propofol inhibited calcium responses to nicotine in glomus cells but the nicotinic antagonists vecuronium and methyllycaconitine did not inhibit calcium responses to hypoxia. "
5.	Neurodegenerative Diseases (Neurodegenerative Disease) 10/01/2021 - "These findings suggest there are some limitations on using systemic nicotinic antagonists to probe the involvement of nicotinic receptors in aspects of dlPFC-dependent working memory function, necessitating alternative strategies to understand the role of this system in cognitive deficits seen in aging and neurodegenerative disease."

Related Drugs and Biologics

1.	Nicotine
2.	Mecamylamine
3.	Hexamethonium (Hexamethonium Bromide)
4.	Dihydro-beta-Erythroidine
5.	Cholinergic Agents (Cholinergics)
6.	Tubocurarine (Tubocurarine Chloride)
7.	Nicotinic Receptors (Nicotinic Acetylcholine Receptor)
8.	Calcium
9.	Bungarotoxins (alpha-Bungarotoxin)
10.	Nicotinic Agonists